Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells

Gynecologic Oncology

Volumn 119, Issue 3, 2010, Pages 549-556

  Taylor Harding, Barbie ^a   Orsulic, Sandra ^a   Karlan, Beth Y ^a,b   Li, Andrew J ^a,b  

^a BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Fluvastatin; Ovarian cancer; Ras pathway; Statin; Synergy

Indexed keywords

CISPLATIN; FARNESYL DIPHOSPHATE; FLUINDOSTATIN; GERANYLGERANYL PYROPHOSPHATE; PHYTOENE SYNTHASE; RAB PROTEIN; RAC1 PROTEIN; RAP1 PROTEIN; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; OVARIAN NEOPLASMS; PRENYLATION; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 78149359469     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.08.017     Document Type: Article

References (43)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer Statistics, 2010 CA Cancer J Clin 2010 [Electronic publication ahead of print, Jul 7]
2. R.C. Bast Jr., B. Hennessy, and G.B. Mills The biology of ovarian cancer: new opportunities for translation Nat Rev Cancer 9 2009 415 428
3. M.F. Oliver Statins prevent coronary heart disease Lancet 346 1995 1378 1379
4. J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, and P.W. MacFarlane Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N Engl J Med 333 1995 1301 1307
5. J.L. Goldstein, and M.S. Brown Regulation of the mevalonate pathway Nature 343 1990 425 430
6. J.A. Kaye, and H. Jick Statin use and cancer risk in the General Practice Research Database Br J Cancer 90 2004 635 637
7. G.D. Friedman, E.D. Flick, N. Udaltsova, J. Chan, C.P. Quesenberry Jr., and L.A. Habel Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361, 859 recipients Pharmacoepidemiol Drug Saf 17 2008 27 36
8. O. Yu, D.M. Boudreau, D.S. Buist, and D.L. Miglioretti Statin use and female reproductive organ cancer risk in a large population-based setting Cancer Causes Control 20 2009 609 616
9. M.L. Kwan, L.A. Habel, E.D. Flick, C.P. Quesenberry, and B. Caan Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors Breast Cancer Res Treat 109 2008 573 579
10. E.R. Garwood, A.S. Kumar, F.L. Baehner, D.H. Moore, A. Au, and N. Hylton Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer Breast Cancer Res Treat 119 2009 137 144
11. R.G. Elmore, Y. Ioffe, D.R. Scoles, B.Y. Karlan, and A.J. Li Impact of statin therapy on survival in epithelial ovarian cancer Gynecol Oncol 111 2008 102 105
12. L.A. Knight, C.M. Kurbacher, S. Glaysher, A. Fernando, R. Reichelt, and S. Dexel Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay BMC Cancer 9 2009 38
13. D.R. Scoles, X. Xu, H. Wang, H. Tran, B. Taylor-Harding, and A. Li Liver X receptor agonist inhibits proliferation of ovarian carcinoma cells stimulated by oxidized low density lipoprotein Gynecol Oncol 116 2009 109 116
14. S.E. Patton, M.L. Martin, L.L. Nelsen, X. Fang, G.B. Mills, and R.C. Bast Jr. Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines Cancer Res 58 1998 2253 2259
15. K.W. Cheng, R. Agarwal, and G.B. Mills Ras-superfamily GTP-ases in ovarian cancer Cancer Treat Res 149 2009 229 240
16. A.P. Garrett, S.W. Ng, M.G. Muto, W.R. Welch, D.A. Bell, and R.S. Berkowitz ras gene activation and infrequent mutation in papillary serous carcinoma of the peritoneum Gynecol Oncol 77 2000 105 111
17. P. Negre-Aminou, A.K. van Vliet, M. van Erck, G.C. van Thiel, R.E. van Leeuwen, and L.H. Cohen Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors; comparison with other human cell types Biochim Biophys Acta 1345 1997 259 268
18. I.K. Wang, S.Y. Lin-Shiau, and J.K. Lin Suppression of invasion and MMP-9 expression in NIH 3T3 and v-H-Ras 3T3 fibroblasts by lovastatin through inhibition of ras isoprenylation Oncology 59 2000 245 254
19. S.A. Holstein, and R.J. Hohl Synergistic interaction of lovastatin and paclitaxel in human cancer cells Mol Cancer Ther 1 2001 141 149
20. H.B. Deng, H.K. Parekh, K.C. Chow, and H. Simpkins Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells J Biol Chem 277 2002 15035 15043
21. M. Serova, F. Calvo, F. Lokiec, F. Koeppel, V. Poindessous, and A.K. Larsen Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells Cancer Chemother Pharmacol 57 2006 491 499
22. S. Kato, S. Smalley, A. Sadarangani, K. Chen-Lin, B. Oliva, and J. Branes Lipophilic but not hydrophilic statins selectively induce cell death in gynaecological cancers expressing high levels of HMGCoA reductase J Cell Mol Med 14 2010 1180 1193
23. A. Martirosyan, J.W. Clendening, C.A. Goard, and L.Z. Penn Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance BMC Cancer 10 2010 103
24. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
25. M. Barbacid ras genes Annu Rev Biochem 56 1987 779 827
26. W.A. Maltese Posttranslational modification of proteins by isoprenoids in mammalian cells Faseb J 4 1990 3319 3328
27. M.C. Seabra Membrane association and targeting of prenylated Ras-like GTPases Cell Signal 10 1998 167 172
28. O. Fromigue, Z. Hamidouche, and P.J. Marie Statin-induced inhibition of 3-hydroxy-3-methyl glutaryl coenzyme a reductase sensitizes human osteosarcoma cells to anticancer drugs J Pharmacol Exp Ther 325 2008 595 600
29. H. Liu, S.L. Liang, S. Kumar, C.M. Weyman, W. Liu, and A. Zhou Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression Cancer Chemother Pharmacol 63 2009 997 1005
30. J. Lee, I. Lee, C. Park, and W.K. Kang Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells Biochem Biophys Res Commun 339 2006 748 754
31. M. Weis, C. Heeschen, A.J. Glassford, and J.P. Cooke Statins have biphasic effects on angiogenesis Circulation 105 2002 739 745
32. K. Kozar, R. Kaminski, M. Legat, M. Kopec, D. Nowis, and J.S. Skierski Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin Int J Oncol 24 2004 1149 1157
33. W. Feleszko, R. Zagozdzon, J. Golab, and M. Jakobisiak Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice Eur J Cancer 34 1998 406 411
34. C. Denoyelle, M. Vasse, M. Korner, Z. Mishal, F. Ganne, and J.P. Vannier Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study Carcinogenesis 22 2001 1139 1148
35. A. Hakem, O. Sanchez-Sweatman, A. You-Ten, G. Duncan, A. Wakeham, and R. Khokha RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis Genes Dev 19 2005 1974 1979
36. A. Horiuchi, N. Kikuchi, R. Osada, C. Wang, A. Hayashi, and T. Nikaido Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with Lovastatin may be useful for ovarian cancer Cancer Sci 99 2008 2532 2539
37. K.W. Cheng, J.P. Lahad, J.W. Gray, and G.B. Mills Emerging role of RAB GTPases in cancer and human disease Cancer Res 65 2005 2516 2519
38. R. Agarwal, I. Jurisica, G.B. Mills, and K.W. Cheng The emerging role of the RAB25 small GTPase in cancer Traffic 10 2009 1561 1568
39. H. Stenmark Rab GTPases as coordinators of vesicle traffic Nat Rev Mol Cell Biol 10 2009 513 525
40. K.W. Cheng, J.P. Lahad, W.L. Kuo, A. Lapuk, K. Yamada, and N. Auersperg The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers Nat Med 10 2004 1251 1256
41. Y. Fan, X.Y. Xin, B.L. Chen, and X. Ma Knockdown of RAB25 expression by RNAi inhibits growth of human epithelial ovarian cancer cells in vitro and in vivo Pathology 38 2006 561 567
42. M.A. Shibata, C. Kavanaugh, E. Shibata, H. Abe, P.M. Nguyen, and Y. Otsuki Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models Carcinogenesis 24 2003 453 459
43. M.J. Campbell, L.J. Esserman, Y. Zhou, M. Shoemaker, M. Lobo, and E. Borman Breast cancer growth prevention by statins Cancer Res 66 2006 8707 8714